AgingResearch.NewsJoin free

SunRegen Healthcare

CompanySwitzerland

SunRegen Healthcare develops one asset, preclinical (SBC003 in ALS). Mostly small molecule; based in Switzerland.

1
Asset
Furthest stage
Preclinical
0
Trials
0
Signals

Pipeline

1

  • SBC003

    Induces neuroglobin expression via p-body modulation to protect neurons through an endogenous, mutation-agnostic pathway.

    Preclinical, Small molecule, ALS, Alzheimer's disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • People8
  • Similar companies6

Intelligence